Corynebacterium stationis

Corynebacterium stationis: An Encyclopedic Reference

Important Preliminary Note on Classification

Corynebacterium stationis is not itself a dietary supplement, herb, or botanical ingredient consumed directly by humans or animals. It is a bacterium used as an industrial fermentation production organism whose metabolic outputs — principally the nucleotide flavor compounds disodium 5′-inosinate (IMP, E631) and disodium 5′-guanylate (GMP, E627) — are authorized food and feed additives. This article covers the organism's identity, taxonomy, industrial role, the active compounds it produces, the mechanism of action of those compounds, the associated regulatory and safety record, and the limited clinical context in which the organism itself (not its products) has been isolated from humans.

Identity and Taxonomy

Current Nomenclature

Corynebacterium stationis was assigned its current name by Bernard et al. in 2010, when Brevibacterium stationis (ZoBell and Upham 1944) Breed 1953 was transferred to the genus Corynebacterium, designated as Corynebacterium stationis comb. nov., with an emended description of the genus Corynebacterium to include isolates that can alkalinize citrate, published in the International Journal of Systematic and Evolutionary Microbiology 2010; 60:874–879.

Critically, Corynebacterium stationis also encompasses bacteria that had previously been classified as Corynebacterium ammoniagenes, which are now re-classified into Corynebacterium stationis on the basis of nucleotide sequence analysis of 16S rRNA and related methods. This re-classification explains why many industrial patents and older scientific literature refer to the organism under the former name C. ammoniagenes, while current regulatory documents use C. stationis.

Brevibacterium stationis ATCC 14403T, Corynebacterium ammoniagenes ATCC 6872, and two clinical isolates were found to form a single taxon group consistent with the genus Corynebacterium, designated as Corynebacterium stationis comb. nov.

Synonyms and Previous Names

• Achromobacter stationis ZoBell and Upham 1944 (original effective name)
• Brevibacterium stationis (ZoBell and Upham 1944) Breed 1953
• Corynebacterium ammoniagenes (for strains re-classified under C. stationis following the 2010 revision)

The NCBI Taxonomy Browser lists the organism as Corynebacterium stationis (ZoBell and Upham 1944) Bernard et al. 2010, with NCBI Taxonomy ID 1705, and type strain designations including ATCC 14403, CCUG 43497, CIP 104228, DSM 20302, JCM 11611, NBRC 12144, and VKM B-1228. The organism belongs to the phylum Actinomycetota, class Actinomycetes, order Mycobacteriales, family Corynebacteriaceae, genus Corynebacterium.

Microbiological Characteristics

Corynebacterium stationis is a facultative anaerobic, gram-positive bacterium. It is classified as an opportunistic pathogen and is one of more than 42 Corynebacterium species and subspecies found in humans, the majority of which have been linked to opportunistic illness.

Members of the genus Corynebacterium generally are gram-positive, small, pleomorphic, and nonsporing rods that are nonmotile and usually facultatively anaerobic and fermentative.

The type strain of C. stationis (ATCC 14403T and equivalent deposits) can utilize citrate; the inclusion of C. stationis in the genus required that the description of Corynebacterium be amended to include citrate-positive strains.

Natural Sources and Environmental Occurrence

Human excrement, blood, and seawater are commonly used sources from which C. stationis has been isolated. Many corynebacteria or diphtheroids occur widely in nature and as commensals on the skin and mucous membranes of animals, where they are usually of little or no pathogenic significance when recovered from clinical specimens; however, some are reported to cause opportunistic infections in humans.

In Canada's risk classification system, C. stationis is assigned risk group 1, with the note that it is not a security-sensitive biological agent and not a terrestrial animal pathogen under Canadian Food Inspection Agency authority.

Industrial and Biotechnological Role

Overview of Industrial Importance

C. stationis (formerly known as C. ammoniagenes) has emerged as an industrially important species due to its role in nucleotide fermentation. Engineered C. stationis strains can synthesize critical compounds for the food industry, such as inosine monophosphate (IMP), xanthine monophosphate (XMP), and guanine monophosphate (GMP).

Inosine monophosphate (IMP), which has a strong umami taste and is widely commercialized as a food additive, is produced by a fermentation process using Corynebacterium stationis (formerly known as Corynebacterium ammoniagenes).

Key Fermentation Products

The industrial significance of C. stationis is defined by three principal metabolites it can be engineered to overproduce:

• Disodium 5′-inosinate (IMP; E631): A purine nucleotide with potent umami flavor-enhancing properties, used as a food and feed additive.
• Disodium 5′-guanylate (GMP; E627): A guanine nucleotide with comparable flavor-enhancing properties, produced in combination with other organisms.
• Xanthine monophosphate (XMP): An intermediate in purine biosynthesis and a precursor to GMP.

Additionally, riboflavin (vitamin B2), a riboside compound related to nucleotides, can be produced by engineering C. stationis.

Fermentation Methodology

Extensive work on nucleotide manufacturing, one of the most successful microbial fermentation processes, has enabled Corynebacterium stationis to transport nucleotides outside the cell by random mutagenesis; however, the underlying mechanism was long not fully elucidated, hindering applications in transporter engineering.

Research has since identified a nucleotide-exporting major facilitator superfamily (MFS) transporter from the C. stationis genome, along with a hyperactive mutation at the G64 residue. Structural estimation and molecular dynamics simulations suggested that the activity of this transporter improved via two mechanisms: enhancing interactions between transmembrane helices through the conserved "RxxQG" motif along with substrate binding, and trapping substrate-interacting residue for easier release from the cavity.

Traditionally, industrial strains have been developed through random mutagenesis followed by extensive screening focusing on analog resistance and auxotrophy to optimize metabolic performance.

The feed additive form of IMP produced by C. stationis is a highly pure preparation. The feed additive consists of a minimum of 97% (w/w of dry matter) of disodium 5′-inosinate (IMP) as the active substance, produced by fermentation with a strain of Corynebacterium stationis.

Traditional and Historical Use

Corynebacterium stationis as a defined taxonomic entity was not known or used in any traditional medical or culinary tradition. The organism was originally isolated in 1944 by ZoBell and Upham and was not formally reclassified to its current name until 2010. No record exists of any traditional herbalist, Ayurvedic, Traditional Chinese Medicine, or other historical system intentionally using this bacterium or fermentation products derived from it in a medicinal or supplement context.

However, the compounds that C. stationis is now used industrially to produce — principally IMP and GMP — have an indirect historical culinary context. In 1908, the active principle of seaweed kombu was identified as glutamate by Ikeda, whose unique taste he termed umami; 5′-inosinate from dried bonito and 5′-guanylate from dried shiitake mushroom were subsequently also found to have umami taste. These naturally occurring nucleotides in traditional Asian cuisine predate by decades the discovery and industrial use of C. stationis as a production organism.

The industrial fermentation of IMP using organisms now classified as C. stationis (under the earlier name C. ammoniagenes) was pioneered in Japan in the 1960s and 1970s, driven by demand for commercial flavor enhancers to replicate and augment the umami taste present in traditional broths and seasonings.

Key Compounds Produced and Mechanisms of Action

Disodium 5′-Inosinate (IMP, E631)

IMP is the primary commercially relevant product of C. stationis fermentation. Inosine 5′-monophosphate (IMP) and 5′-guanosine monophosphate (GMP) are catabolic products of nucleic acids that are often found alongside glutamate in many meats and vegetables, and are flavor enhancers that elicit an umami sensation.

Umami Taste Mechanism

Umami is one of the five basic taste qualities, and the umami taste of L-glutamate can be drastically enhanced by 5′ ribonucleotides; this synergy is a hallmark of umami taste.

Research has proposed a cooperative ligand-binding model involving the Venus flytrap (VFT) domain of the T1R1 taste receptor subunit, where L-glutamate binds close to the hinge region, and 5′ ribonucleotides bind to an adjacent site close to the opening of the flytrap to further stabilize the closed conformation. The three subunits of the T1R family form two heteromeric receptors: umami (T1R1/T1R3) and sweet (T1R2/T1R3).

In human taste tests, 200 μM of IMP, which does not elicit any umami taste by itself, can increase one's umami taste sensitivity to glutamate by 15-fold.

The taste of L-glutamate can be synergistically increased through the addition of disodium 5′-ribonucleic acids, specifically IMP and GMP. When tasted in isolation, IMP elicits a minimal to weak umami taste, hypothesized to occur due to the interaction of IMP with subthreshold concentrations of L-glutamate in human saliva, demonstrating that IMP and GMP require L-glutamate for full umami taste perception.

The taste synergism between glutamate and 5′-ribonucleotides — including inosinate, guanylate, and adenylate — is a hallmark of umami, and the intensity of umami is markedly enhanced when both types of umami substances are mixed.

Riboflavin (Vitamin B2)

Genetically engineered bacteria including Corynebacterium ammoniagenes (now classified as C. stationis) have been successfully constructed for riboflavin production; these bacteria have the capability to effectively transform D-glucose into riboflavin, which can significantly shorten the production cycle and enhance the riboflavin yield. Riboflavin produced via this fermentation route is biochemically identical to naturally occurring vitamin B2.

Scientific Evidence by Area of Use

IMP as a Flavor Enhancer and Palatability Agent

Nature of evidence: Human sensory psychophysics, regulatory assessments, and animal feeding studies.

Umami has been a major culinary influence in Eastern cultures for over a century and has gradually become an important factor in Western diets. Research on umami — especially the unique taste elicited by monosodium glutamate and its synergistic interaction with ribonucleotides such as IMP — has played an important role in discovering peripheral taste receptors, cellular and molecular transduction mechanisms, and the neuroanatomy of the gustatory system.

In humans, the taste response to a glutamate–5′-inosinate mixture is approximately eight times larger than that to glutamate alone. Since glutamate and 5′-inosinate are contained in various foods, umami induced by this synergism occurs in daily eating, making it the main form of umami perception in humans.

The first electrophysiological studies on umami taste were conducted with rats and cats; unlike humans, these animals did not show a large synergism between MSG and GMP or IMP, and their taste nerve responses to umami substances were not differentiated from salt responses. The canine taste system, by contrast, was sensitive to umami substances and showed a large synergism between MSG and GMP or IMP.

The evidence base for IMP's umami-enhancing activity in humans rests on well-replicated sensory psychophysics. However, this is a flavor physiology literature, not a therapeutic or clinical efficacy literature; IMP produced by C. stationis is evaluated and regulated as a food additive, not as a drug or nutraceutical.

IMP as a Feed Additive (Animal Palatability)

Nature of evidence: Regulatory review by EFSA FEEDAP Panel; animal studies.

Multiple formal regulatory assessments by the European Food Safety Authority (EFSA) Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) have evaluated IMP produced by C. stationis strains specifically for use in animal feed and water for drinking.

The FEEDAP Panel expressed reservations on the use of the additive in water for drinking due to concerns on its impact on the hygienic conditions of the water, while concluding that the additive is efficacious to contribute to the flavour of feed.

The feed additive consists of a minimum of 97% of disodium 5′-inosinate (IMP) as an active substance produced by fermentation. The additive is intended for use directly in feedingstuffs or through premixtures and water for drinking, with proposed maximum levels of 25 mg IMP/kg feedingstuffs.

A separate application evaluated proposed maximum levels of 50 mg IMP/kg feedingstuffs, with use also in water for drinking.

The strength of this evidence is sufficient for regulatory approval of palatability enhancement in animals, but does not constitute human clinical evidence for therapeutic health effects.

No Established Therapeutic Uses

A thorough search of the peer-reviewed literature and regulatory databases (EFSA, JECFA, NCCIH, NIH ODS) does not reveal any clinical trials or systematic reviews examining C. stationis itself, or IMP/GMP produced by it, as a therapeutic dietary supplement for any human health condition. The evidence base is confined to: (1) flavor physiology and sensory science; (2) animal feed palatability; and (3) industrial fermentation biotechnology. Any claims about direct health benefits of consuming these fermentation products beyond flavor enhancement are not supported by the current scientific literature.

Body Systems and Health Areas Associated with IMP (the Primary Fermentation Product)

Gustatory / Sensory System

The primary documented biological activity of IMP (the main product of C. stationis fermentation) is in the gustatory system. Sweet, umami, and bitter tastes are mediated by G protein-coupled receptors (GPCRs). Receptors for umami and sweet taste are closely related; the three subunits of the T1R family form two heteromeric receptors: umami (T1R1/T1R3) and sweet (T1R2/T1R3).

Bitter Taste Suppression

IMP has been shown to act as a partial insurmountable antagonist at the hTAS2R16 bitter taste receptor; the synergism of IMP with umami substances extends to the suppression of hTAS2R16 signaling. This finding has implications for food formulation, as IMP may contribute to masking bitterness as well as enhancing umami.

Purine Metabolism

IMP is a purine nucleotide that participates in normal purine biosynthetic pathways. For individuals with gout, the risk of uric acid elevation from disodium inosinate remains low at typical dietary intakes, as purine conversion contributes minimally to overall serum levels. This assessment is not derived from a prospective clinical study but reflects the biochemical reasoning applied in safety evaluations.

Regulatory Status and Authorized Dosages

Human Food Use

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has not assigned a numerical acceptable daily intake (ADI) for disodium inosinate (IMP), instead specifying it for use in amounts consistent with good manufacturing practice.

Safety evaluations by JECFA have established no numerical ADI limit, reflecting its low toxicity profile based on biochemical similarity to natural nucleotides and absence of genotoxic or carcinogenic concerns at typical dietary levels. The European Food Safety Authority (EFSA) has approved its use as a food additive (E631) based on prior evaluations.

The compound is generally produced commercially through bacterial fermentation of sugars using microorganisms like Corynebacterium stationis or via extraction from animal tissues such as fish or meat.

Animal Feed Use: Specific Authorized Concentrations

In animal feed, the following specific concentrations have been evaluated by EFSA:

• IMP produced using C. stationis KCCM 80161: proposed maximum levels of 25 mg IMP/kg feedingstuffs when used directly in feed or through premixtures.
• IMP produced by C. stationis KCCM 80235: the feed additive consisting of a minimum of 97% (w/w of dry matter) of IMP is proposed at maximum levels of 50 mg IMP/kg feedingstuffs.

These concentrations are for animal feed contexts only and do not constitute recommended human supplement dosages.

Safety Considerations

Safety of IMP as a Food Additive

IMP produced using C. stationis KCCM 80161 is considered safe for the target species (animals), for the consumer and for the environment; it is considered not toxic by inhalation, not irritant to skin or eyes, and not a dermal sensitiser.

Safety of Non-Genetically-Modified Strains

EFSA has evaluated multiple distinct C. stationis production strains. For non-genetically-modified strains:

The production strain KCCM 80161 is not genetically modified. Viable cells of the production strain were not detected in the final additive. The additive does not give rise to any safety concern regarding the production strain.

Safety of Genetically-Modified Strains: Initial Uncertainties and Resolution

The evaluation of the genetically-modified strain KCCM 80235 was more complex. The production strain KCCM 80235 is genetically modified and resistant to streptomycin. No viable cells were detected in the final product; however, uncertainties remained on the genetic basis of the streptomycin resistance and on the possible presence of recombinant DNA from the production strain in the final product, meaning the FEEDAP Panel initially could not conclude on the safety of the additive for the target species, consumers, users, and the environment.

Following additional data submission by the applicant, this uncertainty was resolved: the applicant provided supplementary data which elucidated the genetic basis of the streptomycin resistance of the production strain and excluded the presence of its DNA in the final product; therefore, the FEEDAP Panel concluded that IMP produced by C. stationis KCCM 80235 is safe for the target species, consumers, users and the environment.

Hygienic Concerns for Use in Drinking Water

The FEEDAP Panel reiterated its concerns on the safety of the use of IMP in water for drinking due to hygienic reasons. This concern relates to the potential for nucleotide-enriched water to support microbial growth rather than any direct toxicological issue with the compound itself.

Safety of C. stationis as an Organism in Clinical Context

Corynebacterium stationis is a facultative anaerobic gram-positive bacterium and an opportunistic pathogen that is one of more than 42 Corynebacterium species and subspecies found in humans, the majority of which have been linked to opportunistic illness.

Coryneforms including C. stationis are rare, opportunistic human pathogens — Gram-positive bacilli or coccobacilli. These coryneform bacteria are increasingly being recognized as causing opportunistic disease under specific circumstances, such as in patients who are immunocompromised, have prosthetic devices, or have been in hospitals or nursing homes for extended periods.

Clinical isolates of what is now classified as C. stationis have been obtained from blood cultures — including from a 62-year-old male with a chest infection and a 66-year-old female — and were originally identified as most like Corynebacterium species by 16S rRNA gene sequencing.

Mastitis in cattle can be associated with C. stationis, characterized by inflammation of the mammary gland; milk from infected cows is contaminated with bacteria, posing a public health consideration.

Antibiotic Resistance Considerations

In clinical and veterinary contexts, antibiotic resistance is a relevant safety consideration for Corynebacterium species broadly. When infection by Corynebacterium spp. occurs, it is generally opportunistic, occurring in immunosuppressed hosts where skin breakdown and/or trauma has occurred; the most common causative agents in clinical settings include C. jeikeium, C. aurimucosum/minutissimum group, C. propinquum/pseudodiphtheriticum group, C. resistens, and C. striatum. C. stationis is less frequently cited in clinical infection literature than these other species.

In the industrial fermentation context, the streptomycin resistance of the genetically-modified C. stationis KCCM 80235 strain prompted specific regulatory scrutiny: EFSA could not initially conclude on safety due to uncertainties on the genetic basis of the streptomycin resistance of the production strain and on the possible presence of its recombinant DNA in the final product; after the applicant provided supplementary data, the Panel concluded the product is safe.

Purine-Sensitive Individuals

Individuals sensitive to purines may experience mild effects similar to those from high-purine foods when consuming products containing IMP derived from C. stationis fermentation, though the relevance at typical additive-level exposures is considered low by regulatory bodies.

Interactions

No specific drug–IMP or drug–GMP interactions have been identified in the regulatory monographs or the peer-reviewed literature at the concentrations typically encountered through food additive exposure. The compounds IMP and GMP are endogenous nucleotides present naturally in all organisms and in many foods. The only relevant interaction documented in the scientific literature is the potentiation relationship between IMP and glutamate in the umami taste system — a physiological interaction at the gustatory receptor level, not a pharmacological drug–drug interaction.

Summary of Evidence Strength

• Umami flavor synergy of IMP: Well-established; supported by robust sensory psychophysics in humans, receptor biology, and electrophysiology. Evidence strength: strong for the specific claim of flavor enhancement.
• Animal feed palatability enhancement: Supported by EFSA regulatory review and feeding studies. Evidence strength: adequate for regulatory purposes within defined species and concentrations.
• Industrial riboflavin production via C. stationis: Established at the research and patent level; the organism has been engineered to overproduce riboflavin, but this application is less commercially prominent than IMP/GMP fermentation.
• Therapeutic health benefits of IMP as a dietary supplement: No human clinical trials identified. Evidence: absent in the reviewed literature.
• Safety of IMP food additive at typical use levels: Supported by JECFA and EFSA evaluations; no numerical ADI assigned, consistent with very low toxicological concern.

References

• EFSA FEEDAP Panel (2023). Safety of the feed additive consisting of disodium 5′-inosinate (IMP) produced by Corynebacterium stationis KCCM 80235 for all animal species. EFSA Journal 2023;21(4):7958. PMC.
• EFSA FEEDAP Panel (2022). Safety and efficacy of a feed additive consisting of disodium 5′-inosinate (IMP) produced by Corynebacterium stationis KCCM 80235 for all animal species. EFSA Journal 2022;20(3):7153. PMC.
• EFSA FEEDAP Panel (2020). Safety and efficacy of IMP (disodium 5′-inosinate) produced by fermentation with Corynebacterium stationis KCCM 80161 for all animal species. EFSA Journal 2020;18(6):6140. Wiley Online Library.
• EFSA FEEDAP Panel (2021). Safety and efficacy of a feed additive consisting of disodium 5′-guanylate produced with Corynebacterium stationis KCCM 10530 and Escherichia coli K-12 KFCC 11067 for all animal species. EFSA Journal 2021;19(6):6619. PMC.
• EFSA FEEDAP Panel (2023). Safety and efficacy of IMP (disodium 5′-inosinate) produced by fermentation with Corynebacterium stationis KCCM 80161 for all animal species. PMC.
• Bernard KA et al. (2010). Assignment of Brevibacterium stationis to the genus Corynebacterium, as Corynebacterium stationis comb. nov. Int J Syst Evol Microbiol 60:874–879. Microbiology Society.
• List of Prokaryotic names with Standing in Nomenclature (LPSN). Corynebacterium stationis. DSMZ.
• NCBI Taxonomy Browser. Corynebacterium stationis (Taxonomy ID: 1705). National Center for Biotechnology Information.
• Mutational analysis in Corynebacterium stationis MFS transporters for improving nucleotide bioproduction. PMC (Applied Microbiology and Biotechnology, 2024).
• Impact of exporter proteins and their engineering on the productivity of Corynebacterium. Applied Microbiology and Biotechnology 2025. PMC.
• Zhang F et al. (2008). Molecular mechanism for the umami taste synergism. Proceedings of the National Academy of Sciences 105(52):20930–20934. PNAS.
• Ninomiya Y (2015). Umami the Fifth Basic Taste: History of Studies on Receptor Mechanisms and Role as a Food Flavor. BioMed Research International. PMC.
• Beauchamp GK (2023). The flavor-enhancing action of glutamate and its mechanism involving the notion of kokumi. npj Science of Food.
• Mouritsen OG & Styrbæk K (2019). Umami as an 'Alimentary' Taste. A New Perspective on Taste Classification. Nutrients 11(1):182. PMC.
• An underestimated pathogen: Corynebacterium species. Journal of Clinical Microbiology. American Society for Microbiology.
• Funke G & Bernard KA (2012). The Genus Corynebacterium and Other Medically Relevant Coryneform-Like Bacteria. PMC (Manual of Clinical Microbiology).